Trial Profile
A Phase Ⅰ Study of PI3K/mTOR Dual Inhibitor WXFL10030390 to Evaluate the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs WXFL 10030390 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shanghai Jiatan Pharmatech
- 17 Apr 2023 Status changed from recruiting to completed.
- 08 Jun 2021 Results (Data cut off 10 Feb 2021, n=25) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 16 Nov 2018 New trial record